AstraZeneca inks $555 million gene-editing technology deal with Algen, FT reports

Science

AstraZeneca inks $555 million gene-editing technology deal with Algen, FT reports

Mon, Oct 6, 2025 0 Comments

Audio By Carbonatix

(Reuters) -AstraZeneca has signed a $555 million deal with a San Francisco-based biotech business Algen Biotechnologies, The Financial Times reported on Monday.

The agreement with Algen gives AstraZeneca exclusive rights to develop and commercialise therapies from the Crispr gene-editing technology, the report said.

Reuters could not immediately confirm the FT report.

(Reporting by Raechel Thankam Job in Bengaluru; Editing by Rashmi Aich)

Previous Former England rugby captain Lewis Moody diagnosed with ALS

Next Nobel medicine prize goes to researchers into immune system precision

Salem News Channel | Today

More Science Headlines

Other News to Consider

Follow SRNNews.com

on Facebook

@SRNNews

Subscribe to our Newsletters RSS Feeds

Salem Media, our partners, and affiliates use cookies and similar technologies to enhance your browsing experience, analyze site traffic, personalize site content, and deliver relevant video recommendations. By using this website and continuing to navigate, you consent to our use of such technologies and the sharing of video viewing activity with third-party partners in accordance with the Video Privacy Protection Act and other privacy laws. Privacy Policy

X CLOSE

Email to a Friend

AstraZeneca inks $555 million gene-editing technology deal with Algen, FT reports

(Reuters) -AstraZeneca has signed a $555 million deal with a San Francisco-based biotech business Algen Biotechnologies, The Financial Times reported on Monday. The agreement with Algen gives AstraZeneca exclusive rights to develop and commercialise therapies from the Crispr gene-editing technology, the report said. Reuters could not immediately confirm the FT report. (Reporting by Raechel Thankam […]

X close